Covered recipient · General Payments record
CODY HORN
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
General Payments · PY2019–2024
$1,291.01
- Reported across 48 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $381.48 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $139.75 | 8 |
| Acerta Pharma LLC | $123.80 | 1 |
| ABBVIE INC. | $33.28 | 2 |
| DEXCOM, INC. | $23.12 | 1 |
| CHIESI USA, INC. | $20.48 | 1 |
| Alexion Pharmaceuticals, Inc. | $16.78 | 1 |
| Amgen Inc. | $14.54 | 1 |
| CeQur Corporation | $9.73 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.85 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103938815 | CMS |
| ABBVIE INC. | $13.43 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103938817 | CMS |
| Alexion Pharmaceuticals, Inc. | $16.78 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093977472 | CMS |
| Amgen Inc. | $14.54 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111601386 | CMS |
| AstraZeneca Pharmaceuticals LP | $123.80 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104413065 | CMS |
| CeQur Corporation | $9.73 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126846874 | CMS |
| Chiesi USA, Inc. | $20.48 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151808729 | CMS |
| Dexcom, Inc. | $23.12 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153292881 | CMS |
| Gilead Sciences, Inc. | $3.75 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133642810 | CMS |
| Gilead Sciences, Inc. | $23.43 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133642812 | CMS |
| Gilead Sciences, Inc. | $25.42 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133642814 | CMS |
| Gilead Sciences, Inc. | $29.88 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133642816 | CMS |
| Gilead Sciences, Inc. | $4.65 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133642818 | CMS |
| Gilead Sciences, Inc. | $12.50 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133642820 | CMS |
| Gilead Sciences, Inc. | $16.18 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133642822 | CMS |
| Gilead Sciences, Inc. | $23.94 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133642824 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.